Reaction
Angioimmunoblastic T-Cell Lymphoma reporting signals
As of the last recalculation, Angioimmunoblastic T-Cell Lymphoma appears in 308 FAERS reports alongside 4 co-occurring drug terms. The strongest observed disproportionality signal is BRENTUXIMAB VEDOTIN (PRR 260.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Brentuximab Vedotin | 35 | 260.2 | 261.1 |
| Sarilumab | 10 | 26.4 | 26.4 |
| Guselkumab | 11 | 21.5 | 21.5 |
| Axicabtagene Ciloleucel | 3 | 20.7 | 20.7 |